

Title (en)

STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc

Title (de)

STABILE PHARMAZEUTISCHE FLÜSSIGFORMULIERUNGEN DES FUSIONSPROTEINS TNFR:FC

Title (fr)

FORMULATIONS LIQUIDES PHARMACEUTIQUES STABLES DE LA PROTÉINE DE FUSION TNFR:FC

Publication

EP 2699265 A1 20140226 (EN)

Application

EP 12715107 A 20120419

Priority

- EP 11163171 A 20110420
- EP 2012057119 W 20120419
- EP 12715107 A 20120419

Abstract (en)

[origin: WO2012143418A1] The present invention relates to stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc comprising different buffer systems and stabilizers. In particular, it could be demonstrated that the physical stability of TNFR:Fc is significantly improved by using a citrate buffer system and lysine as stabilizer.

IPC 8 full level

A61K 47/12 (2006.01); **A61K 38/00** (2006.01); **A61K 47/18** (2006.01)

CPC (source: EP KR RU US)

A61K 9/08 (2013.01 - KR); **A61K 31/198** (2013.01 - KR); **A61K 38/1793** (2013.01 - EP RU US); **A61K 47/12** (2013.01 - EP KR RU US);
A61K 47/18 (2013.01 - KR); **A61K 47/183** (2013.01 - EP US); **A61P 1/04** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 15/00** (2017.12 - EP);
A61P 17/02 (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/28** (2017.12 - EP);
A61P 29/00 (2017.12 - EP); **A61P 31/14** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/08** (2017.12 - EP);
C07K 14/7151 (2013.01 - RU US); **C07K 2319/30** (2013.01 - EP US)

Citation (search report)

See references of WO 2012143418A1

Citation (third parties)

Third party :

WO 2011141926 A2 20111117 - INTAS BIOPHARMACEUTICALS LTD [IN], et al

Cited by

EP2869817A4; EP2869816A4; US9662396B2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2012143418 A1 20121026; AU 2012244764 A1 20131031; AU 2012244764 B2 20161013; BR 112013026883 A2 20211207;
CA 2833427 A1 20121026; CA 2833427 C 20190924; EP 2699265 A1 20140226; EP 2699265 B1 20191016; ES 2759931 T3 20200512;
JP 2014519484 A 20140814; JP 5996631 B2 20160921; KR 101673654 B1 20161107; KR 20140027274 A 20140306;
RU 2013151303 A 20150527; RU 2614257 C2 20170324; US 2014186351 A1 20140703; US 9453067 B2 20160927

DOCDB simple family (application)

EP 2012057119 W 20120419; AU 2012244764 A 20120419; BR 112013026883 A 20120419; CA 2833427 A 20120419;
EP 12715107 A 20120419; ES 12715107 T 20120419; JP 2014505615 A 20120419; KR 20137030316 A 20120419; RU 2013151303 A 20120419;
US 201214112587 A 20120419